Siva Therapeutics Inc.
Nanotechnology-enabled photothermal therapy for skin cancer
This article was originally published in Start Up
Executive Summary
Siva Therapeutics Inc. aims to destroy skin cancer cells from within by using its SivaRods, gold nanoparticles that combine with near-infrared light to create precisely targeted hyperthermia that destroys tumors with minimal collateral damage.
You may also be interested in...
Medtech Start-Ups Innovate In Treating Advanced Skin Cancer
Nanotechnology, electroporation, and superficial radiotherapy are some of the tools device start-ups are deploying as alternatives to toxic drug regimens and surgery for treating skin cancer. We profile three emerging companies in this issue: OncoSec Medical, Sensus Healthcare, and Siva Therapeutics.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.